In a new study entitled “Tumor necrosis factor-alpha single nucleotide polymorphisms in juvenile systemic lupus erythematosus” researchers investigated genetic variants, specifically those known as single nucleotide polymorphisms, within the gene tumor necrosis factor-alpha (TNF-a), a potent pro-inflammatory cytokine that was previously suggested to play a role in juvenile…
The Senate Appropriations Committee’s 2016 spending bill passed June 25 includes some good news for people with lupus. Sandra C. Raymond, President & CEO of the Lupus Foundation of America notes in a statement that the bill provides support for funding of valuable lupus research and education programs, and…
Dr. Christine A. Peschken from the University of Manitoba in Winnipeg presented data on lupus disease in a Canadian cohort of patients, during the 70th Annual Meeting of The Canadian Rheumatology Association (CRA) in Quebec, Canada. The poster was entitled “Residual Lupus Disease Activity in a…
Recent findings might help ease concerns for women suffering with lupus and interested in having a child. New research concluded that most women diagnosed with lupus and whose disease is not very active can go through a safe pregnancy. The results were published in the Annals of Internal Medicine. It has been suggested that women with…
Kadmon Corporation, LLC, a biopharmaceutical company focused on autoimmune, fibrotic, metabolic diseases and the oncology field, recently announced promising preclinical data on its KD025 drug in the treatment of systemic lupus erythematosus (SLE). The data was presented in May 2015 at the American Association of Immunologists (AAI) Annual…
Susan Manzi, Chair of the Department of Medicine at Allegheny Health Network, was recently presented with the Lupus Foundation of America’s (LFA) National Advocacy Leadership Award. The LFA awarded those with exquisite and distinguished researched who lead and support biomedical innovation to accelerate the development of novel treatments for illnesses such as lupus.
Anthera Pharmaceuticals recently announced it has completed the enrolment of patients for its CHABLIS-SC1 Phase 3 study evaluating blisibimod as a lupus treatment. The company expects to have final data from the trial by the end of 2016. “Reaching our enrollment target for CHABLIS-SC1 ahead of schedule is an important accomplishment,” said in…
An international team led by researchers at the University of Bergen in Norway and the Weizmann Institute of Science in Israel recently published in the journal Immunity their finding that mutations in a gene known as autoimmune regulator (AIRE) are linked to different autoimmune phenotypes.
An international team of researchers recently published in the journal Nature Materials new findings on the activation of the body’s immune response in autoimmune disorders like systemic lupus erythematosus (SLE) and psoriasis. The study is entitled “Liquid-crystalline ordering of antimicrobial peptide–DNA complexes controls TLR9…
During the recent European League Against Rheumatism Annual Congress (EULAR 2015) that took place June 11-13 in Rome, Italy, new clinical recommendations for patients with systemic lupus erythematosus (SLE) and/or antiphospholipid syndrome (APS) who are trying to conceive or are currently pregnant were presented by the league. These new recommendations…